The distribution of serum reproductive hormones in premenopausal and postmenopausal breast cancer patients / 中国综合临床

ABSTRACT

Objective To explore the relationship between serum reproductive hormone levels and premenopausal and postmenopausal breast cancer patients.Methods We recruited healthy women and breast cancer patients who came to our hospital from September 2007 to February 2012 for routine physical examination or surgery and divided them into premenopausal healthy group Ⅰ and breast cancer group Ⅰ ;Postmenopausal healthy group Ⅱ and breast cancer group Ⅱ,with 175 cases in each group.Reproductive hormone levels was measured in all cases.Results There were significant differences among the four groups on estradiol (E2),testosterone (T),progesterone (P),luteotropic hormone (LH),follicle-stimulating hormone (FSH),and prolactin (PRL) (F =76.459,57.224,82.932,161.047,74.801 and 15.246 respectively,P ＜ 0.05).In premenopausal casesThere were significant statistical difference on the levels of E2 [(61.5 ±32.2) ng/L vs.(74.1 ±41.6) ng/L],T [(48.1 ±22.2) μg/L vs.(80.1 ±41.8) μg/L],P [(2.9±1.6) μg/Lvs.(3.5 ±1.3) μg/L],LH [(1.3 ±0.9) U/L vs.(3.5 ±1.4) U/L],FSH [(14.8 ±8.9) U/L vs.(25.1 ±23.3) U/L],PRL [(15.8 ±6.7) μg/L vs.(39.4 ±27.4) μg/L] between the healthy Ⅰ group and the breast cancer Ⅰ group (P ＜ 0.05).In postmenopausal casesThere were significant statistical difference on the E2 [(18.8 ± 8.3) ng/L vs.(55.9±34.1) ng/L],T [(34.1 ±16.2) μg/L vs.(84.7 ±66.4) μg/L],P [(1.3 ±0.9) μg/L vs.(3.5 ±1.4) μg/L],LH [(38.1 ±33.7) U/L vs.(45.6 ± 31.2) U/L] in healthy group Ⅱand the breast cancer Ⅱ group (P ＜ 0.05).The difference was statistically significant on the E2 [(74.1 ± 41.6) ng/L vs.(55.9±34.1) ng/L],LH [(3.5 ±1.4) U/L vs.(45.6 ±31.2) U/L],FSH [(25.1 ±23.3) U/L vs.(70.5±58.2) U/L],PRL [(39.4 ±27.4) μg/L vs.(15.9 ±15.5) μg/L] between the breast group of premenopausal and postmenopausal (P ＜ 0.05).Conclusion Reproductive hormone levels has important clinical significance for the onset and development of breast cancer and provides a reference point for the treatment of menopausal and post-menopausal breast cancer.